Compare BLLN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | FOLD |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | N/A | 2006 |
| Metric | BLLN | FOLD |
|---|---|---|
| Price | $96.06 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $126.71 | $27.25 |
| AVG Volume (30 Days) | 771.8K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.29 | $20.50 |
| Revenue Next Year | $30.14 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.96 | $5.66 |
| 52 Week High | $138.70 | $14.50 |
| Indicator | BLLN | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 74.18 |
| Support Level | $79.07 | $14.21 |
| Resistance Level | $97.36 | N/A |
| Average True Range (ATR) | 7.92 | 0.02 |
| MACD | 0.95 | -0.00 |
| Stochastic Oscillator | 58.11 | 100.00 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.